Quality Assurance Investigations and Impurity Characterization during Upscaling of [¹⁷⁷Lu]Lu-PSMA^I&T

[¹⁷⁷Lu]Lu-PSMA^I&T is widely used for the radioligand therapy of metastatic castration-resistant prostate cancer (mCRPC). Since this kind of therapy has gained a large momentum in recent years, an upscaled production process yielding multiple patient doses in one batch has been...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Stefan Schmitl, Julia Raitanen, Stephan Witoszynskyj, Eva-Maria Patronas, Lukas Nics, Marius Ozenil, Victoria Weissenböck, Thomas L. Mindt, Marcus Hacker, Wolfgang Wadsak, Marie R. Brandt, Markus Mitterhauser
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	MDPI AG 2023-11-01
Saila:	Molecules
Gaiak:	[<sup>177</sup>Lu]Lu-PSMA<sup>-I&T</sup> radiolysis radioligand therapy upscaling quality assurance HPLC
Sarrera elektronikoa:	https://www.mdpi.com/1420-3049/28/23/7696
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!